Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The Pan-FLT3/BTK Multi-kinase Inhibitor CG806 Induces AML Killing in FLT-mutant and Wild Type Cells, and Exerts Synergistic Pro-apoptotic Effects with Concomitant Targeting of Anti-apoptotic Bcl-2 and/or Mcl-1
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer
Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis
Purity: 99.9% CAS No.: 2692623-94-0 Formula: C 10 H 17 D 3 ClNO 4 Molecular Weight:256.74 Storage: -20C, sealed storage, away from moisture * In solvent : -80C, 6 months
OZEMPIC Tablets: Recommended Dosage Follow the OZEMPIC tablets starting, escalation, and maintenance dosage described below to reduce the risk of GI adverse reactions [see Warnings and Precautions ( 5.6), Adverse Reactions (6.1)] : Starting Dosage (Initiation Phase) (Days 1 through 30) : The recommended starting dosage is 1.5 mg orally once daily (this dosage is not effective for glycemic control)
G., Moxley, R
US$ 22.01
US$ 26.02
US$ 22.33
